Catch-up vaccination for HBV-related morbidity :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Impact of hepatitis B catch-up vaccination on hepatitis B-related chronic health issues

Hepatitis B virus Hepatitis B virus
Hepatitis B virus Hepatitis B virus

The hepatitis B virus (HBV) induces chronic liver infections, raising the risk of cirrhosis and liver cancer.

See All

Key take away

Healthcare providers should consider missed-dose vaccination for those with incomplete HBV vaccination to prevent long-term complications like liver cancer and chronic infection.

Background

The hepatitis B virus (HBV) induces chronic liver infections, raising the risk of cirrhosis and liver cancer. While a three-dose HBV vaccine from birth is effective, the benefit of catch-up vaccination for those with unfinished or no vaccination is ambiguous. This investigation aimed to examine the impact of HBV catch-up vaccination on lowering morbidity in children and adults.

Method

A search of ChinaXiv, MEDLINE, Cochrane Central Register of Controlled Trials, MedRXIV, BioRXIV, Google Scholar and; ongoing and finished trials on the USA, China, and WHO platforms was conducted, with the last search on June 30, 2023. Experimental and observational studies, meta-analyses/systematic reviews, completed trials, and preprints that evaluated the effectiveness of catch-up hepatitis vaccination in lowering morbidity from hepatitis B viral infection [including acute and chronic hepatitis B, cirrhosis and hepatocellular carcinoma (HCC)], without age or language limitations were assessed.

The grade of the included studies was independently assessed using the Newcastle-Ottawa Scale for cohort and cross-sectional studies. Evidence certainty was defined using the GRADE approach. Categorical data were presented as numbers (%) and differences between groups as relative risk (RR) or odds ratio (OR). The Review Manager 5.4 was used to pool the data.

Result

Out of 4 included observational studies, one provided data for both children and adults [two studies focused on children (one with data on adults), and three on adults]. The cross-sectional study was evaluated as high quality, while the 3 cohort studies as fair to good.

A high-certainty pediatric study showed that catch-up vaccination for those aged 9 to 18 years reduced hepatitis B surface antigen (HBsAg) positivity [RR: 0.09], lowered HBV DNA detection [RR: 0.084], and increased anti-HBs seroconversion [RR: 2.08], with high-quality evidence due to the large treatment effect. The mass HBV immunization for children aged 0 to 10 years decreased HBsAg and anti-HBc prevalence while increasing anti-HBs seroconversion after vaccination as per a separate low-certainty Italian study.

As for the adults, 3 studies with low-certainty evidence were included. Two studies informed a decreased rate of acute hepatitis B [OR: 0.08 (0.05, 0.12), I2=33%]. Another study showed HBV vaccination reduced HCC prevalence (incidence ratio: 0.04), highlighting its benefit in preventing HCC with chronic HBV avoidance. Due to issues with directness and study design, these studies were rated as low quality.

Conclusion

Catch-up hepatitis B vaccination in adult populations effectively reduces the occurrence of acute hepatitis B and HCC. It also lowers the prevalence of HBsAg and anti-HBc while providing anti-HBs protection in individuals aged 0 to 18 years.

Source:

Acta Medica Philippina

Article:

HBV Catch-up Vaccination in Children and Adults with Incomplete or Unknown Vaccination to Reduce Hepatitis B-related Morbidity: A Systematic Review

Authors:

Germana Emerita V. Gregorio, Sarah Jane G. Velasco-Aro

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: